Sökning: (WFRF:(Wallentin Lars)) pers:(Oldgren Jonas)
> (2015-2019) >
Comparison of dabig...
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation : Results from the RE-LY trial
-
Brambatti, Michela (författare)
-
Darius, Harald (författare)
-
- Oldgren, Jonas (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
visa fler...
-
Clemens, Andreas (författare)
-
Noack, Herbert H. (författare)
-
Brueckmann, Martina (författare)
-
Yusuf, Salim (författare)
-
- Wallentin, Lars (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
Ezekowitz, Michael D. (författare)
-
Connolly, Stuart J. (författare)
-
Healey, Jeff S. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2015
- 2015
- Engelska.
-
Ingår i: International Journal of Cardiology. - : Elsevier BV. - 0167-5273 .- 1874-1754. ; 196, s. 127-131
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: Diabetes mellitus (DM) is frequent among patients with atrial fibrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efficacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6% vs. 76.5%), coronary artery disease (37.4% vs. 24.9%) and peripheral vascular disease (5.6% vs. 3.2%); (all p < 0.01). Time in therapeutic range for warfarin-treated patients was 65% for diabetic versus 68% for non-diabetic patients (p < 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9% per year vs. 1.3% per year, p < 0.001). DM was also associated with an increased risk of death (5.1% per year vs. 3.5% per year, p < 0.001) and major bleeding (4.2% per year vs. 3.0% per year, p < 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59% per year vs. 0.05% per year; dabigatran 150 mg: 0.89% per year vs. 0.51% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identifier: NCT00262600.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Diabetes mellitus
- Atrial fibrillation
- Stroke
- Dabigatran
- Warfarin
- Oral anticoagulation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Brambatti, Miche ...
-
Darius, Harald
-
Oldgren, Jonas
-
Clemens, Andreas
-
Noack, Herbert H ...
-
Brueckmann, Mart ...
-
visa fler...
-
Yusuf, Salim
-
Wallentin, Lars
-
Ezekowitz, Micha ...
-
Connolly, Stuart ...
-
Healey, Jeff S.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Uppsala universitet